Kidney Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Renal Cell Carcinoma (352)

Kidney Medullary Carcinoma (92)

Renal Cell Carcinoma (352)

Kidney Medullary Carcinoma (92)

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week (New B) belzutifan Sensitive : A2 Merck (MSD) Press Release - 1wk	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week belzutifan Sensitive : A2 Merck (MSD) Press Release - 1 week - (New B)
SETD2 deletion	Clear Cell Renal Cell Carcinoma	SETD2 deletion	Clear Cell Renal Cell Carcinoma	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks (New D) talazoparib Sensitive : D Cancer Res - 2wk	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks talazoparib Sensitive : D Cancer Res - 2 weeks - (New D)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) ABT-869 Sensitive : C3 BMC Cancer - 3wk	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks ABT-869 Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) midostaurin Sensitive : C3 BMC Cancer - 3wk	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks midostaurin Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vinblastine Sensitive : C3 BMC Cancer - 3wk	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vinblastine Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vorinostat Sensitive : C3 BMC Cancer - 3wk	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vorinostat Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
TNFRSF18-H	Renal Cell Carcinoma	TNFRSF18-H	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks (New C3) nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3wk	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : C1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : C1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2

Kidney Cancer

Associations(380)

Associations
(380)